Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)

BACKGROUND: Recently, the addition of antiprogrammed cell death‐ligand 1 (PD‐L1) monoclonal antibodies, including durvalumab and atezolizumab to platinum‐based chemotherapy, has demonstrated clinical benefits in patients with untreated advanced small cell lung cancer (SCLC). However, these clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Hidenobu, Azuma, Koichi, Shimose, Takayuki, Yoshioka, Hiroshige, Kurata, Takayasu, Shingu, Naoki, Okamoto, Masaki, Kawashima, Yosuke, Okamoto, Isamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807442/
https://www.ncbi.nlm.nih.gov/pubmed/36380738
http://dx.doi.org/10.1111/1759-7714.14727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807442/
https://www.ncbi.nlm.nih.gov/pubmed/36380738
http://dx.doi.org/10.1111/1759-7714.14727

Ejemplares similares